Advanced search
Add to list

Phase III randomized AUGMENT study of Lenalidomide/Rituximab vs Rituximab/Placebo in Patients with relapsed/refractory indolent non-hodgkin lymphoma

Author
Organization
Keywords
follicular lymphoma, indolent lymphoma, lenalidomide, marginal zone, lymphoma, NHL, rituximab

Citation

Please use this url to cite or link to this publication:

MLA
Gribben, J. et al. “Phase III Randomized AUGMENT Study of Lenalidomide/Rituximab Vs Rituximab/Placebo in Patients with Relapsed/refractory Indolent Non-hodgkin Lymphoma.” British Journal of Haematology. Vol. 185. Hoboken: Wiley, 2019. 79–79. Print.
APA
Gribben, J., Trneny, M., Izutsu, K., Fowler, N. H., Hong, X., Zhu, J., Zhang, H., et al. (2019). Phase III randomized AUGMENT study of Lenalidomide/Rituximab vs Rituximab/Placebo in Patients with relapsed/refractory indolent non-hodgkin lymphoma. BRITISH JOURNAL OF HAEMATOLOGY (Vol. 185, pp. 79–79). Presented at the 59th Annual Scientific Meeting of the British-Society-for-Hematology, Hoboken: Wiley.
Chicago author-date
Gribben, J., M. Trneny, K. Izutsu, N. H. Fowler, X. Hong, J. Zhu, H. Zhang, et al. 2019. “Phase III Randomized AUGMENT Study of Lenalidomide/Rituximab Vs Rituximab/Placebo in Patients with Relapsed/refractory Indolent Non-hodgkin Lymphoma.” In British Journal of Haematology, 185:79–79. Hoboken: Wiley.
Chicago author-date (all authors)
Gribben, J., M. Trneny, K. Izutsu, N. H. Fowler, X. Hong, J. Zhu, H. Zhang, Fritz Offner, A. Scheliga, G. Nowakowski, A. Pinto, F. Re, L. M. Fogliatto, P. Scheinberg, I. Flinn, C. Moreira, D. Liu, S. Kalambakas, P. Fustier, C. Wu, and J. P. Leonard. 2019. “Phase III Randomized AUGMENT Study of Lenalidomide/Rituximab Vs Rituximab/Placebo in Patients with Relapsed/refractory Indolent Non-hodgkin Lymphoma.” In British Journal of Haematology, 185:79–79. Hoboken: Wiley.
Vancouver
1.
Gribben J, Trneny M, Izutsu K, Fowler NH, Hong X, Zhu J, et al. Phase III randomized AUGMENT study of Lenalidomide/Rituximab vs Rituximab/Placebo in Patients with relapsed/refractory indolent non-hodgkin lymphoma. BRITISH JOURNAL OF HAEMATOLOGY. Hoboken: Wiley; 2019. p. 79–79.
IEEE
[1]
J. Gribben et al., “Phase III randomized AUGMENT study of Lenalidomide/Rituximab vs Rituximab/Placebo in Patients with relapsed/refractory indolent non-hodgkin lymphoma,” in BRITISH JOURNAL OF HAEMATOLOGY, Glasgow, SCOTLAND, 2019, vol. 185, pp. 79–79.
@inproceedings{8618778,
  author       = {Gribben, J. and Trneny, M. and Izutsu, K. and Fowler, N. H. and Hong, X. and Zhu, J. and Zhang, H. and Offner, Fritz and Scheliga, A. and Nowakowski, G. and Pinto, A. and Re, F. and Fogliatto, L. M. and Scheinberg, P. and Flinn, I. and Moreira, C. and Liu, D. and Kalambakas, S. and Fustier, P. and Wu, C. and Leonard, J. P.},
  booktitle    = {BRITISH JOURNAL OF HAEMATOLOGY},
  issn         = {0007-1048},
  keywords     = {follicular lymphoma,indolent lymphoma,lenalidomide,marginal zone,lymphoma,NHL,rituximab},
  language     = {eng},
  location     = {Glasgow, SCOTLAND},
  pages        = {79--79},
  publisher    = {Wiley},
  title        = {Phase III randomized AUGMENT study of Lenalidomide/Rituximab vs Rituximab/Placebo in Patients with relapsed/refractory indolent non-hodgkin lymphoma},
  volume       = {185},
  year         = {2019},
}

Web of Science
Times cited: